274 results on '"Kulbe, Hagen"'
Search Results
2. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication
3. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
4. High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
5. Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma
6. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
7. LRP1B—a prognostic marker in tubo-ovarian high-grade serous carcinoma
8. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer
9. ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium
10. Pre-Operative Malnutrition in Patients with Ovarian Cancer: What Are the Clinical Implications? Results of a Prospective Study
11. Pre-operative Malnutrition in Patients with Ovarian Cancer: What are the Clinical Implications? Results of a Prospective Study
12. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation
13. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis
14. Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer
15. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
16. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism
17. In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
18. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium
19. In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
20. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
21. Supplementary Table S5 from IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
22. Supplementary Figure 1 from An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells
23. Supplementary Tables 1-3 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
24. Supplementary Figure 3 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
25. Supplementary Figures S1-S5 from IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
26. Supplementary Figure 1 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
27. Supplementary Table 1 from An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells
28. Supplementary Figure 2 from An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells
29. Supplementary Methods from IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
30. Supplementary Figure 2 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
31. Supplementary Table 4 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
32. Supplementary Figure Legends 1-3 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
33. Data from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
34. Supplemental Figure Legends from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
35. Supplementary Figure 4 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
36. Supplementary Figure 3 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
37. Supplementary Table 2 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
38. Supplementary Figure Legends 1-4 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
39. Supplementary Figure 5 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
40. Supplementary Figure 2 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
41. Supplementary Figure 3 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
42. Supplementary Figure 1 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
43. Supplementary Table 1 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
44. Supplementary Figure 4 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
45. Data from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer
46. Supplementary Figure 2 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
47. Supplementary Figure 1 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
48. ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium
49. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
50. Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.